Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results